IRIS PubliCatt

Chiricozzi, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.943
EU - Europa 1.823
AS - Asia 1.098
AF - Africa 116
SA - Sud America 22
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.017
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.906
SG - Singapore 483
SE - Svezia 466
IT - Italia 412
IE - Irlanda 312
ID - Indonesia 216
CN - Cina 201
DE - Germania 191
RU - Federazione Russa 129
CI - Costa d'Avorio 113
IN - India 65
GB - Regno Unito 63
FI - Finlandia 49
FR - Francia 46
HK - Hong Kong 36
CA - Canada 31
ES - Italia 29
NL - Olanda 26
JP - Giappone 22
CZ - Repubblica Ceca 18
AU - Australia 12
TR - Turchia 12
RO - Romania 11
TH - Thailandia 10
BE - Belgio 9
CH - Svizzera 9
IR - Iran 9
UA - Ucraina 9
BR - Brasile 7
AT - Austria 6
GR - Grecia 6
IQ - Iraq 6
KR - Corea 6
HU - Ungheria 5
PE - Perù 5
SA - Arabia Saudita 5
HR - Croazia 4
IL - Israele 4
LT - Lituania 4
PT - Portogallo 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BO - Bolivia 3
CL - Cile 3
CO - Colombia 3
MY - Malesia 3
NP - Nepal 3
PL - Polonia 3
BG - Bulgaria 2
CY - Cipro 2
DO - Repubblica Dominicana 2
EU - Europa 2
ME - Montenegro 2
MX - Messico 2
NO - Norvegia 2
PK - Pakistan 2
RS - Serbia 2
SI - Slovenia 2
VN - Vietnam 2
AM - Armenia 1
AR - Argentina 1
BD - Bangladesh 1
EE - Estonia 1
JO - Giordania 1
KZ - Kazakistan 1
LU - Lussemburgo 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 5.017
Salva come PNG Salva come JPEG
Città #
Ashburn 428
Chandler 425
Singapore 351
Dublin 308
Jakarta 211
Abidjan 113
Bremen 113
Milan 109
New York 104
Moscow 102
Princeton 99
Beijing 77
Boston 75
Rome 66
Wilmington 39
Helsinki 36
Hong Kong 34
Washington 31
San Mateo 30
Los Angeles 28
Pune 28
Frankfurt am Main 27
Chicago 26
London 23
Seattle 21
Paris 19
Munich 18
Brno 15
Amsterdam 14
Hangzhou 14
Redwood City 14
Dearborn 13
Lappeenranta 13
Boardman 10
Fairfield 10
Ottawa 10
Barcelona 9
Brussels 9
Toronto 9
Boydton 8
Busto Arsizio 8
Chiang Mai 8
Norwalk 8
Cattolica 7
Houston 7
Montreal 7
Nanjing 7
Shanghai 7
Ōtsu 7
Edinburgh 6
Madrid 6
Naples 6
Redmond 6
Vienna 6
Woodbridge 6
Zurich 6
Andover 5
Atlanta 5
Bologna 5
Chiyoda-ku 5
Feasterville Trevose 5
Hyderabad 5
Nuremberg 5
Southampton 5
St Petersburg 5
Tokyo 5
Augusta 4
Budapest 4
Englewood 4
Lima 4
Messina 4
Monmouth Junction 4
Stockholm 4
White Salmon 4
Adapazarı 3
Ankara 3
Asansol 3
Bern 3
Brasov 3
Cagliari 3
Chengdu 3
Cinisello Balsamo 3
Cosenza 3
Esslingen am Neckar 3
Genoa 3
Harrison 3
Hot Springs 3
Jeddah 3
Kathmandu 3
Kish 3
Kuala Lumpur 3
La Paz 3
Leawood 3
Melbourne 3
Monza 3
Mumbai 3
Mussidan 3
Nanchang 3
Nijmegen 3
North Charleston 3
Totale 3.357
Salva come PNG Salva come JPEG
Nome #
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study 161
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study 109
Clinical and ultrasonographic profile of adalimumab-treated hidradenitis suppurativa patients: A real-life monocentric experience 81
Improvement of severe facial seborrheic dermatitis following low-dose isotretinoin therapy 79
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis 72
Assessment of alopecia areata universalis successfully treated with upadacitinib 61
Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments 61
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 61
Biological agents targeting interleukin-13 for atopic dermatitis 61
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 56
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 56
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 55
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 54
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 53
A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic 53
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa 52
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis 51
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 51
COVID-19 hygiene measures: hand eczema and insights into ACE2 and integrins as key molecules for SARS-CoV-2 cutaneous transmission 50
Long-term management of moderate-to-severe adult atopic dermatitis: A consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 49
Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience 48
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches 46
A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis 45
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 44
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis 43
Characterization of comorbid conditions burdening hidradenitis suppurativa: A multicentric observational study 43
Alexithymia affects patients with hidradenitis suppurativa 41
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 41
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 40
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 40
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study 40
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 40
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 39
Dusky red swelling of the penis in association with fever and diarrhoea: a quiz. Metastatic Crohn's disease of the penis associated with enteric Crohn's disease 39
Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study 39
A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis 39
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis 38
Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis 38
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab 38
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 37
Topical treatment of severe xerosis: Results of an observational study 37
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study 36
Successful treatment with secukinumab in an HIV-positive psoriatic patient after failure of apremilast 36
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia 36
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 36
Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study 35
Authors’ reply to Borg and Thoning: “Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study” 35
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 35
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data 34
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 34
Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis 34
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus 34
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 34
Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study 34
European consensus statement on phenotypes of pustular psoriasis 34
Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study 33
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis 33
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore 32
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 32
Mapping exercise and status update of eight established registries within the TREatment of ATopic eczema (TREAT) Registry Taskforce 31
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 31
Successful use of anti‐IL‐23 molecules in overweight‐to‐obese psoriatic patients: a multicentric retrospective study 30
Immunologic biomarkers for clinical and therapeutic management of psoriasis 30
Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: Joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) 30
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 29
Gynecomastia following isotretinoin treatment: A rare endocrine side effect 29
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 28
Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis 28
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 28
Bimekizumab 28
The risk of covid-19 pandemic in patients with moderate to severe plaque psoriasis receiving systemic treatments 28
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern 28
The preclinical discovery and development of deucravacitinib for the treatment of psoriasis 27
Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting 27
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 26
Investigational systemic drugs for moderate to severe plaque psoriasis: What's new? 25
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 25
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 24
TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand 24
The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit 24
Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience 24
Biomolecular index of therapeutic efficacy in psoriasis treated with anti-TNF-α agents 24
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 23
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 23
The role of insomnia in the vulnerability to depressive and anxiety symptoms in atopic dermatitis adult patients 23
Current therapeutic paradigm in pediatric atopic dermatitis: Practical guidance from a national expert panel 23
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study 23
Optimizing acitretin use in patients with plaque psoriasis 23
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (ritonavir, atazanavir, emtricitabine, tenofovir) 23
The effects of systemic immunomodulatory treatments on COVID-19 outcomes in patients with atopic dermatitis: Results from the global SECURE-AD registry 22
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis 22
Efficacy and safety of infliximab in psoriatic patients over the age of 65 22
Serum Protein Profile Changes in Psoriatic Patients Undergoing Treatment With Infliximab 22
Spotlight on dupilumab in the treatment of atopic dermatitis: Design, development, and potential place in therapy 22
UVA-1 Laser in the treatment of palmoplantar pustular psoriasis 22
Unmet needs in atopic dermatitis management: an expert consensus 22
Response to the article by Narla et al “Management of inadequate response and adverse effects to dupilumab in atopic dermatitis” 21
Elderly psoriatic patients under biological therapies: an Italian experience 21
Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis 21
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 20
Totale 3.824
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.894
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.894
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202082 0 0 0 0 0 3 1 15 1 18 32 12
2020/202194 2 2 3 6 3 6 5 23 11 12 20 1
2021/2022466 47 2 13 11 17 4 8 45 20 96 91 112
2022/20231.894 152 189 143 311 100 235 150 176 233 61 103 41
2023/20241.859 45 374 116 272 85 252 121 90 39 93 147 225
2024/2025726 60 40 286 66 274 0 0 0 0 0 0 0
Totale 5.176